Navigation Links
Sangamo BioSciences Presents Clinical Data From Key SB-728-T HIV Studies: Proof Of Concept For Ongoing Sustained Functional Control Of HIV Viral Load; Cytoxan Preconditioning Successfully Enhances Engraftment
Date:12/6/2013

RNA levels are >10,000 copies/ mL for three consecutive weeks or their CD4 T-cell count drops below 500 cells/mm3 for two consecutive weekly measurements.

Two additional cohorts of three subjects each will be treated at doses of 2000mg/m2 and 3000mg/m2, respectively.

About SB-728-T
Sangamo's drug, SB-728-T, is generated by ZFN-mediated modification of the gene encoding the CCR5 receptor in a patient's own T-cells.  ZFN modification disrupts the expression of this key co-receptor for HIV entry and renders cells resistant to HIV infection. The approach is based on the observation that a naturally occurring mutation in the CCR5 gene, CCR5 delta-32, provides protection from HIV infection. Individuals in whom both copies of the CCR5 gene carry the delta-32 mutation are generally not susceptible to the most common strain of HIV.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 and Phase1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. As part of its acquisition of Ceregene Inc., Sangamo acquired a fully-enrolled and funded, double-blind, placebo-controlled Phase 2 trial to evaluate NGF-AAV (CERE-110) in Alzheimer's disease. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell fun
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
2. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
3. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
4. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
5. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
6. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
7. Sangamo BioSciences Reports First Quarter 2013 Financial Results
8. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
9. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
10. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
11. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... WHITEHOUSE STATION, N.J. , Sept. 19, 2014 Merck ... the United States and Canada , ... on Desafiando La Diabetes: Logra Tus Metas , an educational ... of their blood sugar -- a key treatment goal to help ... the United States are at a higher risk for ...
(Date:9/19/2014)... Five MinuteClinic walk-in medical clinics are opening inside select CVS/pharmacy stores ... opened in Memphis and Cordova ... in Springfield on September 24 and a ... open October 22.  MinuteClinic is the largest and fastest growing provider ... . The Memphis -area clinics join ...
(Date:9/19/2014)... Mass. , Sept. 19, 2014  Pressure ... today announced it has received and approved all ... HT48 instruments and has begun to manufacture the ... first instrument will be ready for shipment by ... built and released at a rate of about ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3
... June 27 /CNW/ -,Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; ... a clinical trial,comparing CellCept (oral mycophenolate mofetil, MMF) ... of care, for,inducing treatment response in the induction ... rates were similar in both arms, the trial ...
... WIRE)--Jun 27, 2007 - PrimeCell(TM),Therapeutics LLC (http://www.primecelltherapeutics.com) ... pre-clinical,studies for a clinical trial to assess ... bone marrow stem cells into,spinal cord injury ... preliminary report at the 13th,Annual Meeting of ...
Cached Medicine Technology:Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis 2Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis 3Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis 4Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis 5Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis 6Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis 7Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis 8Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for,Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical,Study 2
(Date:9/21/2014)... Young women starting college understand the benefits of a ... But they aren,t confident they can follow through on ... The study involved 268 female college freshmen ... and Eating Right program. The students answered food-related questions ... they were very busy with school work, were very ...
(Date:9/21/2014)... To accommodate the ever-growing customer base, Angeldress.co.uk decided to ... Recently, the company has unveiled its 2014 vintage ... wedding gowns, Angeldress.co.uk wants to make sure that all ... way. Its high quality vintage wedding outfits are now ... 62% off. , Online shopping is becoming more and ...
(Date:9/21/2014)... BambooIndustry.com, an experienced producer of natural bamboo items, has ... http://www.bambooindustry.com/products/bamboo-panel/ ). The company’s excellent panels are very popular ... discounted prices now, from 10 to 30 percent off. ... are available in many specifications; they are promised to ... finely manufactured by qualified workers. They are specially offered ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 Top10BestSEOHosting.com, ... ( http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the most ... want to buy high quality hosting products. ... good hosting suppliers; we recommend two great hosting ... says, “We believe that iPage and GreenGeeks are ...
(Date:9/20/2014)... 6 Minutes to Skinny , a fat ... that is showing men and women of all ages how ... fat using simple 6-minute exercises and easy-to-follow lifestyle tips daily, ... review. , “When it comes to losing body fat, ... for all people,” reports Michaels. “Metabolism plays a big role ...
Breaking Medicine News(10 mins):Health News: College Women Can Use Food Strategies, Study Finds 2Health News:Angeldress.co.uk Launches New Range Of 2014 Vintage Wedding Dresses In Its Online Store 2Health News:Discounted Bamboo Panels For Sale At BambooIndustry.com 2Health News:Leading Review Website Top10BestSEOHosting.com Unveils The Best Hosting Suppliers In September 2Health News:6 Minutes to Skinny: Review Exposes Craig Ballantyne’s Method to Jump Starting the Metabolism and Blasting Away Body Fat in Just 6 Minutes Per Day 2
... use of narcotics for chronic pain in elderly works, ... the dose. On the other hand, the use of ... increase in the dosage with serious health repercussions. ... morphine, methadone and oxycodone. Opioid drugs are used for ...
... for creating stem cells that may be used to help ... lines are an exact match with the patients’ DNA and ... into using stem cells cloned from the persons to use ... first time human embryonic stem cells have been found suitable ...
... New study had found out that colonoscopy may be ... ,For patients suspected with colorectal cancer, flexible sigmoidoscopy ... of 1cm in diameter, adenomas with dysplasia, or cancer. ... neoplasia that may be cancerous for women who were ...
... may increase the risk of bacterial infection of the lungs, ... Medicine. ,Researchers had studied persons of age between 2 ... each of 635 persons with invasive pneumococcal disease, 10 persons ... defined by the study as proof of diagnosis of asthma ...
... among patients of colon cancer after undergoing surgery can reduce ... a study which was presented at the annual meeting of ... recurrence reduces by about 50% for the patients who took ... from colon cancer. ,Colon and rectum together form the ...
... Children suffering from Attention Deficit Hyperactivity Syndrome (ADHD) may ... help of sensory interventions like applying deep pressure or ... Hyperactivity Disorder (ADHD) is a condition that affects nearly ... early school years. Children with ADHD are known to ...
Cached Medicine News:
... Heavy Duty is a pressure relief mattress overlay ... specifically to the BariKare® Bed., ,INDICATIONS , ... lbs., Large patients at risk or suffering from ... mattress that would benefit from a pressure relief ...
... bariatric bed system which helps provide comfort ... care setting, ,INDICATIONS: ,Patients weighing up ... 2) ,Healthcare frame accommodating one or two ... ,CONTRAINDICATION: ,Total weight in excess of ...
... The BariMaxx™ is a full-featured healthcare ... environment for the care and management of ... up to 1000 lbs. ,Large patients at ... weight in excess of 1000 lbs. (including ...
EC+ Extra Care Bariatric Bed...
Medicine Products: